Epigral Limited
HSBC Mutual Fund decreased its stake in Epigral from 2.56% to 1.50%, selling 4,60,050 shares.
An integrated manufacturer of specialty chemicals, Epigral produces a diverse range of chemical products for industrial applications across multiple sectors including pharmaceuticals, agrochemicals, and specialty materials. The company operates integrated manufacturing facilities that enable vertical control over production processes and supply chains. Epigral serves customers globally with customized chemical solutions and maintains a commitment to sustainable manufacturing practices.
Indian arm of HSBC Asset Management, the investment arm of HSBC Group with over USD 600 billion in global AUM. Manages over Rs 1 lakh crore in India across equity, debt and hybrid schemes. Previously known for integration of L&T Mutual Fund schemes after acquiring it from L&T Finance in 2022, which significantly expanded the franchise.